Journal
BRITISH JOURNAL OF CANCER
Volume 105, Issue 6, Pages 847-853Publisher
SPRINGERNATURE
DOI: 10.1038/bjc.2011.294
Keywords
circulating tumour cell; breast cancer; prostate cancer; lung cancer; CellSearch; ISET
Categories
Ask authors/readers for more resources
BACKGROUND: Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we compared the performance of two CTC detection systems based on the expression of the EpCAM antigen (CellSearch assay) or on cell size (ISET assay). METHODS: Circulating tumour cells were enumerated in 60 patients with metastatic carcinomas of breast, prostate and lung origins using CellSearch according to the manufacturer's protocol and ISET by studying cytomorphology and immunolabelling with anti-cytokeratin or lineage-specific antibodies. RESULTS: Concordant results were obtained in 55% (11 out of 20) of the patients with breast cancer, in 60% (12 out of 20) of the patients with prostate cancer and in only 20% (4 out of 20) of lung cancer patients. CONCLUSION: Our results highlight important discrepancies between the numbers of CTC enumerated by both techniques. These differences depend mostly on the tumour type. These results suggest that technologies limiting CTC capture to EpCAM-positive cells, may present important limitations, especially in patients with metastatic lung carcinoma. British Journal of Cancer (2011) 105, 847-853. doi: 10.1038/bjc.2011.294 www.bjcancer.com Published online 9 August 2011 (C) 2011 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available